Niagen Bioscience, Inc. (NAGE) income statement
NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3015% below fair value
$1.94−0.10 (-4.90%)
Close on Nov 18, 2026Market cap $153.50MP/E 16.2Yield –
Niagen Bioscience, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 63.9%
- Operating margin
- 3.9%
- Net margin
- 8.4%
- Return on equity, FY2025
- 28.3%
Financial strength
- Current ratio
- 5.93
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 411.1%
Valuation
- P/E ratio
- 16.2
- Price to sales
- 1.26
- Price to book
- 1.85
- Dividend yield
- –
See a number that looks wrong?